(Q45766371)

English

Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?

scientific article published on 12 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

5

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

3

object named as

Tore K Kvien

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

2

object named as

Sofia Ramiro

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

Annelies Boonen

6

object named as

Annelies Boonen

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

1

object named as

Polina Putrik

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

author name string

Tuulikki Sokka

4

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

Equity in Clinical Eligibility Criteria for RA treatment Working Group

7

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

language of work or name

0 references

publication date

12 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

73

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

11

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

2010-2021

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203819

21 January 2018

Inequities in access to biologic and synthetic DMARDs across 46 European countries

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203819

21 January 2018

Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203819

21 January 2018

Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203819

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203819

21 January 2018

QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203819

21 January 2018

Correlation and simple linear regression

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203819

21 January 2018

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203819

21 January 2018

Treating rheumatoid arthritis to target: recommendations of an international task force

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203819

21 January 2018

Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203819

21 January 2018

Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203819

21 January 2018

Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid arthritis (RA): lessons from QUEST RA.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203819

21 January 2018

Effectiveness and efficiency of guideline dissemination and implementation strategies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203819

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203819

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2013-203819

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/23940213

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45766371&oldid=1744871848"